CAR T-cell therapy moving to frontline as myeloma treatment
Originally published in BioNews Report says most doctors see therapies becoming standard 1st-line treatment Most doctors who treat multiple myeloma expect that CAR T-cell therapies will soon became the standard first-line treatment, according to new research from market analytics company Spherix Global Insights. The trend marks a shift in attitudes among myeloma experts. Last year, doctors tended to report more […]
CAR-T Moves Upstream in Multiple Myeloma as Physicians Signal Shift in Treatment Sequencing
Findings from Spherix Global Insights’ research reveal nearly three-quarters anticipate frontline use, with significant near-term share gains expected in second-line disease Exton, PA – March 19, 2026 — Spherix Global Insights’ Q1 2026 update of RealTime Dynamix™: Multiple Myeloma findings point to a clear inflection in treatment strategy, as physicians grow increasingly confident in CAR-T […]
Conflicting Guidance and Rapid Innovation Leave Physicians Seeking Clarity in Relapsed/Refractory Multiple Myeloma
Spherix Global Insights’ Latest Market Dynamix™ Report Reveals Intensifying Complexity in Relapsed/Refractory Multiple Myeloma Ahead of ASH 2025 Exton, PA., December 2, 2025 – “Relapsed/Refractory Multiple Myeloma (RRMM) is difficult to manage because there’s no clear, consistent guidance – ask five academic physicians and you’ll get five different answers. It’s frustrating trying to optimize care […]
Spherix Global Insights Launches Market Dynamix™: PD-1 Inhibition in Solid Tumors, Delivering a Comprehensive Assessment of Biosimilar and Subcutaneous PD-1 Market Dynamics Across Key Oncology Indications
Exton, PA., October 31, 2025 — Spherix Global Insights has announced the launch of its latest Market Dynamix™ service, PD-1 Inhibition in Solid Tumors (US) 2025, providing an in-depth analysis and advisory services for the evolving immuno-oncology landscape as the next wave of PD-1 biosimilars and subcutaneous (SC) formulations rapidly approach market entry. As leading […]
Spherix Global Insights Expands Hematology Franchise to Include Oncology, Enhancing Advisory Services and Delivering Deeper Physician and Market Insights
Inaugural coverage will include multiple myeloma, myelodysplastic syndrome and B-cell malignancies (large B-cell lymphoma and chronic lymphocytic leukemia). EXTON, PA., October 15, 2025 – Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, today announced the expansion of its hematology franchise to include […]